MAP is the leading global meeting dedicated to precision oncology, defined as molecular profiling of tumours to identify targetable alterations. This oncology field is fast evolving and has now entered the mainstream of clinical practice.

At MAP 2022, international key opinion leaders will explain how to use genomic data for treating cancer patients, matching such data to a specific drug or therapy, based on the genetic drivers detected in the patients’ tumours, and they will debate about the future challenges in precision oncology.

The MAP Congress is the result of a solid partnership among Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and Unicancer, all committed to offering the best care to people with cancer worldwide, through oncology education and research.